133047-46-8

Basic information

• Product Name: 4-Thiazolecarboxaldehyde, 2-(1-methylethyl)- (9CI)
• Synonyms: 4-Thiazolecarboxaldehyde, 2-(1-methylethyl)- (9CI);2-isopropylthiazole-4-carbaldehyde;2-(propan-2-yl)-1,3-thiazole-4-carbaldehyde;2-isopropylthiazol-4-carbaldehyde;2-(1-methylethyl)-4-Thiazolecarboxaldehyde
• CAS NO: 133047-46-8
• Molecular Formula: C₇H₉NOS
• Molecular Weight: 155.21746
• EINECS: 604-604-1
• Product Categories: ISOPROPYL;ALDEHYDE
• Mol File: 133047-46-8.mol

Chemical Properties

• Boiling Point: 232.4°C at 760 mmHg
• Flash Point: 94.4°C
• Appearance: /
• Density: 1.159g/cm³
• Vapor Pressure: 0.0591mmHg at 25°C
• Refractive Index: 1.565
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.10±0.10(Predicted)
• CAS DataBase Reference: 4-Thiazolecarboxaldehyde, 2-(1-methylethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Thiazolecarboxaldehyde, 2-(1-methylethyl)- (9CI)(133047-46-8)
• EPA Substance Registry System: 4-Thiazolecarboxaldehyde, 2-(1-methylethyl)- (9CI)(133047-46-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 133047-46-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Thiazolecarboxaldehyde, 2-(1-methylethyl)(9CI) is used as a key intermediate in the synthesis of new drugs. Its unique chemical structure allows for the development of innovative therapeutic agents with potential applications in treating various diseases and medical conditions.
Used in Agricultural Chemicals Industry:
In the agricultural chemicals industry, 4-Thiazolecarboxaldehyde, 2-(1-methylethyl)(9CI) serves as a building block for the creation of new agrochemicals. Its incorporation into these products can lead to the development of more effective and environmentally friendly pesticides, herbicides, and other agricultural products.
Used in Dyes and Pigments Industry:
4-Thiazolecarboxaldehyde, 2-(1-methylethyl)(9CI) is utilized in the production of dyes and pigments, contributing to the development of new colorants with improved properties. Its unique chemical structure can enhance the color intensity, stability, and other characteristics of the resulting dyes and pigments, making them suitable for various applications, such as textiles, plastics, and printing inks.
Used in Research and Development:
4-Thiazolecarboxaldehyde, 2-(1-methylethyl)(9CI) is also used in research and development for exploring its potential medicinal properties and biological activities. Scientists are investigating its interactions with biological systems to understand its therapeutic potential and identify new applications in the field of medicine.

InChI:InChI=1/C7H9NOS/c1-5(2)7-8-6(3-9)4-10-7/h3-5H,1-2H3

Upstream product

• 133047-45-7 ethyl (2-isopropylthiazol-4-yl)methanol 
• 133047-44-6 2-isopropyl-thiazole-4-carboxylic acid ethyl ester 

Relevant articles and documents

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

HIV protease inhibiting compounds

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Polymer-Supported Bisacetoxybromate(I) Anion - An Efficient Co-Oxidant in the TEMPO-Mediated Oxidation of Primary and Secondary Alcohols

A polymer-bound reagent for the efficient oxidation of primary alcohols to aldehydes and secondary alcohols to ketones in the presence of a catalytic amount of 2,2,6,6-tetramethyl-1-piperidinyloxyl (TEMPO) is described. The oxidation process is particular mild and allows one to prepare aldehydes with α-chirality without racemization. This also includes the synthesis of α-aminoaldehydes. In most cases, work-up of this heavy metal-free oxidation is achieved by simple filtration followed by removal of the solvent. Insight into the role of the bromate(I) anion in the oxidation process was gained from the TEMPO-mediated oxidation of benzaldehyde in the presence of the hypochlorite anion loaded on an anion exchange resin.

HIV protease inhibitors

The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: The effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters

Due largely to the emergence of multi-drug-resistant HIV strains, the development of new HIV protease inhibitors remains a high priority for the pharmaceutical industry. Toward this end, we previously identified a 4-hydroxy-5,6-dihydropyrone lead compound

Retroviral protease inhibiting compounds

The present invention discloses novel compounds, compositions, and methods for inhibiting retroviral proteases and in particular for inhibiting human immunodeficiency virus (HIV) protease. The present invention also relates to compositions and methods for

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption. Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 μM) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.